Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease

AIM OF THE STUDY: Non-alcoholic fatty liver disease (NAFLD) is frequently complicated by dyslipidemia and is considered to be a hepatic manifestation of metabolic syndrome. Pemafibrate is a novel selective peroxisome proliferator-activated receptor-α modulator. There are no reports of the clinical e...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinozaki, Satoshi, Tahara, Toshiyuki, Lefor, Alan Kawarai, Ogura, Masahito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2020
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592096/
https://www.ncbi.nlm.nih.gov/pubmed/33145434
http://dx.doi.org/10.5114/ceh.2020.99528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592096/
https://www.ncbi.nlm.nih.gov/pubmed/33145434
http://dx.doi.org/10.5114/ceh.2020.99528

Ejemplares similares